OraSure Technologies experienced a challenging third quarter in 2025, with total net revenues declining significantly by 32% to $27.1 million compared to the same period last year. This decline was primarily driven by decreases across its core business segments, including Diagnostics and Sample Management Solutions, as well as a near-complete cessation of COVID-19, Risk Assessment Testing, and Molecular Services revenues. Despite the downturn, the company remains optimistic about returning to growth in 2026 through diversification and new product launches, supported by a strong balance sheet.
Total net revenues for Q3 2025 decreased by 32% to $27.1 million from $39.9 million in Q3 2024.
Core revenues, excluding COVID-19, Molecular Services, and Risk Assessment Testing, decreased by 25% year-over-year to $27.0 million.
The company reported a GAAP net loss of $13.7 million and a Non-GAAP net loss of $9.8 million for the quarter.
OraSure maintains a strong cash position with $216.5 million in cash and cash equivalents as of September 30, 2025.
OraSure Technologies is guiding for Q4 2025 total revenues to be between $25 million and $28 million, with COVID-19 testing revenues expected to be less than $100 thousand. The company anticipates a return to growth in 2026, driven by customer diversification and new product launches.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance